Effect of moisture content on solid-state interaction at the interface between magnesium stearate and captopril
Source abstract
Abstract
Abstract A grinding process was used to accelerate the solid-state interaction at the interface between magnesium stearate (MgSt) and captopril (CAP) in the presence or absence of water. The 110 °C-preheated MgSt/CAP or MgSt/CAP ground mixture showed a 5.06% (w/w) or 6.07% (w/w) water content, respectively, which was >4.29% (w/w) for the original MgSt alone. The increased water content in each ground mixture was due to the atmospheric absorption of water caused by grinding. A small infrared (IR) peak at 1562 cm −1 appeared in the IR spectrum of the 110 °C-preheated MgSt/CAP ground mixture, whereas a stronger IR peak at 1541 cm −1 with a shoulder at 1556 cm −1 was observed for the MgSt/CAP ground mixture. These IR peaks were possibly related to the solid-state interaction at the interface between MgSt and CAP via hydrogen bonding of adsorbed water. However, an excess of water added in the MgSt/CAP ground mixture could exacerbate the solid-state interaction of MgSt and CAP to form a stearic acid as evidenced by the IR peak at 1705 cm −1 . This may be due to the neutralization between basic MgSt and acidic CAP. In addition, thermal Fourier transform infrared (FTIR) microspectroscopy also confirmed that the thermal-dependent dehydration process might alter the IR peak intensity of MgSt/CAP ground mixtures.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Drug Solubulity and Delivery Systems · Analytical chemistry methods development · Analytical Chemistry and Sensors
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (24)
Show source-provided references
1. Byrn · Adv. Drug Deliv. Rev. · 2001 · 48 · 11510.1016/S0169-409X(01)00102-8 ↗
2. Excipient choice in solid dosage forms
3. Miller · Int. J. Pharm. · 1988 · 41 · 110.1016/0378-5173(88)90130-5 ↗
4. Patel · Crit. Rev. Ther. Drug Carrier Syst. · 2006 · 23 · 110.1615/CritRevTherDrugCarrierSyst.v23.i1.10 ↗
5. Rao · Pharm. Dev. Technol. · 2005 · 10 · 42310.1081/PDT-54462 ↗
6. Fukui · Int. J. Pharm. · 2001 · 216 · 13710.1016/S0378-5173(01)00580-4 ↗
7. Swaminathan · AAPS Pharm. Sci. Technol. · 2002 · 310.1007/BF02830617 ↗
8. Malan · Drug Dev. Ind. Pharm. · 1997 · 23 · 53310.3109/03639049709149816 ↗
9. Kandarapu · STP Pharm. Sci. · 2001 · 11 · 449
10. Oliveira · J. Therm. Anal. Calorim. · 2005 · 79 · 26710.1007/s10973-005-0047-5 ↗
11. Mann · Presse Med. · 2005 · 34 · 130310.1016/S0755-4982(05)84178-8 ↗
12. Ravera · J. Am. Soc. Nephrol. · 2006 · 17 · S9810.1681/ASN.2005121319 ↗
13. Cheng · J. Phys. Chem. Solids · 2008 · 69 · 100710.1016/j.jpcs.2007.11.015 ↗
14. Lin · Int. J. Pharm. · 2006 · 318 · 8610.1016/j.ijpharm.2006.03.021 ↗
15. Wang · Pharm. Res. · 2004 · 21 · 212710.1023/B:PHAM.0000048206.62093.4e ↗
16. Rajala · Thermochim. Acta · 1995 · 248 · 17710.1016/0040-6031(94)01950-L ↗
17. Bracconi · Thermochim. Acta · 2005 · 429 · 4310.1016/j.tca.2004.11.021 ↗
18. Ertel · J. Pharm. Sci. · 1998 · 77 · 62510.1002/jps.2600770715 ↗
19. Barra · Drug Dev. Ind. Pharm. · 1996 · 22 · 110510.3109/03639049609065947 ↗
20. Wang · J. Pharm. Sci. · 2001 · 90 · 103410.1002/jps.1056 ↗
21. Callahan · Drug Dev. Ind. Pharm. · 1982 · 8 · 35510.3109/03639048209022105 ↗
22. Andres · Int. J. Pharm. · 2001 · 218 · 15310.1016/S0378-5173(01)00624-X ↗
23. 1975
24. Deamer · J. Lipid Res. · 1967 · 8 · 25510.1016/S0022-2275(20)40146-4 ↗